European stocks eked out gains on Friday amid a decline in oil prices.
Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful.
Novartis is discussing options with banks for selling its $13.8 billion stake in rival Roche, though a sale is not imminent.
Roche reiterated on Tuesday that it expects to achieve its full-year targets after sales during the first three months of 2016 rose 4 percent.
European markets finished in the red on Thursday, as a slump in health care stocks weighed on investors, despite a recovery in oil.
The U.S. Food and Drug Administration recommended that blood should no longer be collected from regions where the Zika virus is circulating.
European equities closed sharply lower on Thursday, as a raft of weak earnings offset positive sentiment surrounding the rebound in oil prices.
Drugmaker Roche on Thursday reported full-year earnings and a dividend slightly below forecasts and said it expected sales to grow low- to mid-single digit in 2016.
Goldman's Robert Boroujerdi presented seven future theme predictions and their investment implications in a note to clients Wednesday.
European equities closed the session mixed Wednesday as investors digested inflation numbers and contemplated the possibility of further stimulus.
An FDA rule created to spur drug companies to develop treatments for rare diseases is being used far beyond its original scope, critics say.
European equities closed sharply lower on Friday as slumping commodity prices and weak earnings reports weighed on investor sentiment.
Norway's sovereign wealth fund, the largest in the world by assets, reported a loss in the third quarter of this year as the global sell-off in risk assets hit the fund's equity holdings.
European markets jumped higher on Thursday, after the European Central Bank's president said that policy would be re-examined in December.
Drugmaker Roche said its experimental medicine for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy.
DAX all folks
European stocks ended lower on Thursday, after a flurry of corporate earnings came out from across the region.
Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.
Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.
European equities closed mixed on Monday as investors reacted to new economic data and cheered updates from the pharmaceutical sector.